Nevada State Board of Pharmacy adoption package (R107-25) amends NAC 453.510 (Schedule I) to add dipentylone and seven specified fentanyl-related substances to Nevada’s controlled substances schedules, aligning state controls with federal scheduling actions as described in the informational statement. Compliance impact: entities operating in Nevada that handle controlled substances (e.g., laboratories, research/analytical standard suppliers, forensic and law-enforcement partners, regulated healthcare/pharmacy operations) must treat these newly listed substances as Schedule I under Nevada law (enhanced restrictions on possession/handling, licensing/registration controls, and related compliance program updates).
Nevada State Board of Pharmacy adopted an amendment to NAC 453.510 (Schedule I) adding dipentylone and seven fentanyl-related substances (para-chlorofentanyl; ortho-chlorofentanyl; meta-fluorofuranyl fentanyl; ortho-methylcyclopropyl fentanyl; beta-methylacetyl fentanyl; tetrahydrothiophenyl/tetrahydrothiofuranyl fentanyl; para-fluoro valeryl fentanyl). The adoption record states the purpose is to conform Nevada’s Schedule I list with the federal Controlled Substances Act pursuant to Nevada’s Uniform Controlled Substances Act authorities (e.g., NRS 453.211 and NRS 453.2182). Compliance impact: Nevada registrants handling controlled substances (manufacturers, distributors, pharmacies, researchers, etc.) should update controlled-substance inventories, handling controls, and related policies to reflect these Schedule I additions.
An initial draft proposed regulation (LCB File No. R038-26I) would amend NAC 453.510 (Schedule I) to add the nitazene-related substances N‑pyrrolidino metonitazene (metonitazepyne) and N‑pyrrolidino protonitazene (protonitazepyne). Compliance impact: organizations that may possess or encounter these substances in Nevada (e.g., clinical/toxicology labs, forensic labs, analytical standards suppliers, and other controlled-substance registrants) should track the rulemaking and be prepared to adjust controls and policies if these compounds become Schedule I under Nevada law.
Nevada Legislature-posted Board of Pharmacy meeting agenda/workshop materials indicate proposed amendments to NAC 453 to add the nitazene analogs N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene to Schedule I. This signals additional controlled substance scheduling changes progressing through the state administrative process. If adopted, these substances would be regulated as Schedule I under Nevada’s Uniform Controlled Substances Act implementation (NAC 453), impacting compliance obligations for entities that may handle or encounter these substances (e.g., laboratories, healthcare/controlled-substance registrants, and enforcement).
A Nevada State Board of Pharmacy meeting agenda packet (workshop item) references proposed amendments to Nevada’s controlled substances scheduling rules (NAC 453) to add two nitazene analogs—N-pyrrolidino metonitazene and N-pyrrolidino protonitazene—to Schedule I. The materials indicate the item is under consideration/proposed (not confirmed as adopted within the provided text). Compliance teams should monitor for subsequent adoption notices/amendments if finalized, as Schedule I placement would significantly restrict lawful handling and require registrant controls consistent with Schedule I substances.
The Nevada State Board of Pharmacy posted a first amended agenda (posted Feb 10, 2026) for its March 5, 2026 meeting that includes a workshop item and embedded proposed regulatory text to amend NAC 453.510 (Schedule I) to add the nitazene analogs N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene. If adopted through the Board’s rulemaking process, these substances would be treated as Schedule I controlled substances in Nevada, triggering associated controlled-substance controls (e.g., prohibitions/limitations on possession and handling, and compliance program updates for registrants).
The Nevada State Board of Pharmacy issued a Notice of Hearing/Intent to act upon a regulation proposing amendments to NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada’s Schedule I list under the Uniform Controlled Substances Act framework. The notice schedules a public hearing (March 5, 2026). If adopted, these substances would become subject to Schedule I restrictions, affecting controlled substance compliance programs (e.g., prohibitions/controls on possession, handling, distribution, and associated enforcement exposure).
The Nevada State Board of Pharmacy issued a public hearing notice for LCB File No. R107-25 proposing to amend NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada Schedule I, described as being in conformity with federal regulations. The notice sets a public hearing date of March 5, 2026. If adopted, these additions would expand Nevada’s Schedule I list and affect controlled-substance compliance obligations under NRS 453/NAC 453 for any entities that may encounter these substances (e.g., healthcare, pharmacy, laboratories, enforcement, and supply chain controls).
The Nevada State Board of Pharmacy posted a Notice of Intent to act upon a regulation and scheduled a public hearing to amend NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada Schedule I, stated as conforming with federal Uniform Controlled Substances Act scheduling. If adopted, these substances would become Schedule I controlled substances in Nevada, impacting screening, handling/registration controls, and potential enforcement risk for entities that manufacture, distribute, dispense, or otherwise handle controlled substances in Nevada. The notice also sets the opportunity for stakeholder participation via the hearing and written comments.
The Nevada State Board of Pharmacy issued a Notice of Intent to Act Upon a Regulation / Notice of Hearing (LCB File No. R107-25) proposing to amend NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada Schedule I, stated to be in conformity with federal regulations. A public hearing is scheduled for March 5, 2026, and written comments are due on or before March 5, 2026. Compliance teams should monitor this rulemaking because, if adopted, the substances would become explicitly controlled under Nevada Schedule I, affecting handling prohibitions/controls, registration, security, and recordkeeping obligations under NRS/NAC 453 for registrants and other regulated entities.
Nevada State Board of Pharmacy adoption documentation (R204-24) indicates NAC 453.510 (Schedule I) was amended to add ethylphenidate and 2‑methyl AP‑237 to Nevada’s Schedule I list, as part of maintaining conformity with controlled-substance scheduling under Nevada’s Uniform Controlled Substances Act framework. Compliance impact: regulated Nevada handlers must update controlled-substance controls (inventory, access, procurement, analytical standards, and related compliance documentation) to reflect Schedule I status for these substances under state law.
An informational statement dated January 21, 2026 describes an adopted Nevada State Board of Pharmacy regulation amending NAC 453.510 (Schedule I) to add ethylphenidate and 2‑methyl AP‑237 (2‑MAP) to Nevada’s Schedule I in conformity with federal scheduling. This adoption signals a binding scheduling update in the Nevada administrative rulemaking process; once effective/codified per Nevada procedures, regulated entities should treat these substances as Schedule I for compliance screening, handling controls, and related controlled substance obligations applicable under Nevada law.
An informational statement for an adopted Nevada State Board of Pharmacy regulation reports an amendment to NAC 453.510 (Schedule I) adding ethylphenidate and 2‑methyl AP‑237 to Nevada’s Schedule I list. These additions expand substances regulated as Schedule I under Nevada’s Uniform Controlled Substances Act implementation, affecting compliance for any organization potentially encountering these substances (e.g., prohibitions and controls related to possession, distribution, and enforcement consequences). The document states the change is intended to keep Nevada in conformity with federal controlled substance scheduling.
The Nevada State Board of Pharmacy published a public hearing notice and proposed regulation text to amend NAC 453.510 to add ethylphenidate and 2‑methyl AP‑237 to Schedule I under Nevada’s Uniform Controlled Substances Act implementation. The notice sets a public hearing for Dec. 4, 2025. (Note: a separate later Nevada Register informational statement indicates these substances were subsequently adopted into Schedule I; this record captures the earlier proposal and comment/hearing step.)
Nevada Attorney General Opinion No. 2025-01 provides an official legal interpretation regarding how Nevada controlled substances law (including NRS 453) applies to singly licensed homeopathic physicians. The opinion discusses conditions/limitations for possession, administration, prescribing, and dispensing of controlled substances, including registration expectations (Nevada Board of Pharmacy controlled substances registration and DEA registration) and the limited scope tied to accepted homeopathic practice. Compliance impact: healthcare providers and compliance teams supporting homeopathic practice in Nevada should review the opinion for constraints and registration/oversight expectations when controlled substances are involved.
Nevada Attorney General Opinion No. 2025-01 provides an official legal interpretation addressing issues involving controlled substances under NRS 453 (Nevada Uniform Controlled Substances Act), including discussion of authorization/registration considerations relevant to prescribing/possession in the context analyzed by the opinion. While not a codified amendment, the opinion can materially affect compliance expectations for regulated practitioners and entities by clarifying legal interpretation applied in Nevada.
Nevada Attorney General Opinion No. 2025-01 provides an official legal interpretation concerning the application of NRS 453 (Nevada Uniform Controlled Substances Act) to homeopathic physicians. The opinion discusses whether, and under what limitations, singly licensed homeopathic physicians may possess/administer/prescribe/dispense controlled substances, and emphasizes requirements tied to Board of Pharmacy controlled substances registration and DEA registration. Compliance impact: healthcare providers and compliance teams should review the opinion when evaluating practitioner authority and registration obligations under NRS 453 for controlled substances activities.